GleamWall
中文EN

CRDF Cardiff Oncology, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1213037 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY11.6%
TTM net income YoY25.3%
TTM EPS YoY31.6%
Revenue 3-yr CAGR6.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-7,068.2%
Net margin-6,735.2%
FCF margin—
EBITDA margin-7,005.5%

Returns

ROE-97.9%
ROA-75.2%
ROIC (approx.)-114.1%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets22.8%
Debt / equity0.00x
Current ratio4.21x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.06x
Accruals ratio4.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$171,000$104,000$41,000$243,000$120,000$121,000$109,000$151,000
R&D expense$5.03M$5.92M$6.76M$5.08M$8.20M$11.58M$10.48M$9.71M
SG&A expense$4.36M$3.80M$6.13M$3.00M$3.90M$3.32M$4.01M$3.01M
Operating income-$9.22M-$9.62M-$12.85M-$7.83M-$11.97M-$14.78M-$14.38M-$12.57M
Net income-$8.86M-$9.23M-$12.35M-$7.22M-$11.26M-$13.94M-$13.43M-$11.79M
EBITDA-$9.13M-$9.53M-$12.76M-$7.74M-$11.88M-$14.68M-$14.29M-$12.48M
EPS (basic)-0.12-0.14-0.18—-0.17-0.21-0.20—
EPS (diluted)-0.12-0.14-0.18—-0.17-0.21-0.20—
Weighted avg. shares (diluted)76.18M68.40M68.35M—66.88M66.53M66.52M—
Balance sheet
Cash & equivalents$12.06M$9.20M$8.54M$17.47M$10.13M$10.78M$24.09M$51.47M
Short-term investments$21.73M$25.32M$37.51M$40.83M$50.46M$60.17M$55.79M$40.28M
Receivables$90,000$189,000$191,000$182,000$254,000$526,000$405,000$773,000
Current assets$35.03M$35.59M$47.34M$60.13M$61.80M$73.70M$82.71M$95.05M
PP&E, net$364,000$450,000$491,000$578,000$666,000$666,000$805,000$898,000
Total assets$36.41M$37.33M$49.17M$61.88M$63.78M$75.74M$84.81M$97.19M
Current liabilities$8.32M$10.80M$14.46M$16.39M$14.71M$16.67M$13.29M$13.43M
Total liabilities$8.32M$10.80M$14.46M$16.50M$14.99M$17.13M$13.93M$14.24M
Shareholders' equity$28.10M$26.53M$34.71M$45.39M$48.79M$58.61M$70.88M$82.95M
Shares outstanding77.80M68.50M68.37M68.31M67.09M66.53M66.53M66.52M
Cash flow statement
Operating cash flow-$9.87M-$11.77M-$12.29M-$5.97M-$10.83M-$8.33M-$12.79M-$10.27M
Capital expenditure$4,000——$0$18,000——$0
Free cash flow-$9.88M——-$5.97M-$10.85M——-$10.27M
Investing cash flow$3.61M$12.27M$3.26M$10.75M$10.16M-$4.98M-$14.58M$4.51M
Financing cash flow$9.13M$149,000$105,000$2.55M$25,000$0$3,000$44.19M
Depreciation & amortization$88,000$87,000$87,000$88,000$89,000$94,000$93,000$96,000
Stock-based compensation$1.34M$920,000$1.66M$1.26M$1.38M$1.68M$1.36M$1.20M

Free plan shows the latest 8 periods; Pro shows all 63 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.